Sign up
Pharma Capital

Tissue Regenix chief Antony Odell on their 'transformational' Cellright acquisition

Antony Odell, chief executive of Tissue Regenix PLC (LON:TRX) tells Proactive they're spending US$30mln on Texas-based rival, Cellright Technologies, which will catapult them to the front of  the growing US market for regenerative medicine and bone grafts.

 

View full TRX profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.